GlobeNewswire: GW Pharmaceuticals plc Contains the last 10 of 234 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T03:00:39ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/04/29/2219182/0/en/GW-Pharmaceuticals-recognised-for-leadership-in-prescription-cannabis-based-medicines-with-prestigious-Queen-s-Award-for-Enterprise-in-Innovation.html?f=22&fvtc=4&fvtv=20787GW Pharmaceuticals recognised for leadership in prescription cannabis-based medicines with prestigious Queen’s Award for Enterprise in Innovation2021-04-29T00:00:00Z<![CDATA[GW’s ground-breaking medicines development programme recognised for outstanding achievement in innovation with UK’s highest official award for British business GW’s ground-breaking medicines development programme recognised for outstanding achievement in innovation with UK’s highest official award for British business]]>https://www.globenewswire.com/news-release/2021/04/23/2216250/0/en/GW-Pharmaceuticals-Shareholders-Approve-Acquisition-by-Jazz-Pharmaceuticals.html?f=22&fvtc=4&fvtv=20787GW Pharmaceuticals Shareholders Approve Acquisition by Jazz Pharmaceuticals2021-04-23T20:01:00Z<![CDATA[LONDON and DUBLIN, April 23, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (GW) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (Jazz) today announced that GW’s shareholders voted to approve the acquisition of GW by a subsidiary of Jazz (or its nominee(s)) at the GW shareholder meetings held today. The proposals required to be approved by GW’s shareholders in order to complete the acquisition were each approved. In addition, the non-binding, advisory proposal to approve certain compensation arrangements for GW’s named executive officers was approved. Detailed information regarding the results will be made available by GW in a filing with the U.S. Securities and Exchange Commission (SEC).]]>https://www.globenewswire.com/news-release/2021/04/20/2213053/0/en/GW-Pharmaceuticals-receives-European-Commission-approval-for-EPIDYOLEX-cannabidiol-for-the-treatment-of-seizures-associated-with-tuberous-sclerosis-complex.html?f=22&fvtc=4&fvtv=20787GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex2021-04-20T10:30:00Z<![CDATA[– Tuberous sclerosis complex (TSC) represents a third indication for GW’s cannabidiol in Europe –]]>https://www.globenewswire.com/news-release/2021/04/13/2209105/0/en/GW-Pharmaceuticals-and-U-S-Subsidiary-Greenwich-Biosciences-to-Present-Data-at-the-2021-American-Academy-of-Neurology-AAN-Annual-Meeting.html?f=22&fvtc=4&fvtv=20787GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data at the 2021 American Academy of Neurology (AAN) Annual Meeting2021-04-13T12:30:00Z<![CDATA[EPIDOLEX encore presentations highlight long-term safety and efficacy data in patients with tuberous sclerosis complex (TSC) and other treatment-resistant epilepsies]]>https://www.globenewswire.com/news-release/2021/02/26/2183320/0/en/GW-Pharmaceuticals-receives-positive-CHMP-opinion-for-EPIDYOLEX-cannabidiol-for-use-as-treatment-of-seizures-associated-with-Tuberous-Sclerosis-Complex.html?f=22&fvtc=4&fvtv=20787GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX® (cannabidiol) for use as treatment of seizures associated with Tuberous Sclerosis Complex2021-02-26T12:15:00Z<![CDATA[– If approved by the European Commission (EC), the label for EPIDYOLEX® will expand to include a third indication in Europe – – If approved by the European Commission (EC), the label for EPIDYOLEX® will expand to include a third indication in Europe –]]>https://www.globenewswire.com/news-release/2021/02/16/2175953/0/en/GW-Pharmaceuticals-plc-Reports-Fourth-Quarter-and-Year-End-2020-Financial-Results-and-Operational-Progress.html?f=22&fvtc=4&fvtv=20787GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2020 Financial Results and Operational Progress2021-02-16T12:00:00Z<![CDATA[– Total revenue of $148.2 million for the fourth quarter and $527.2 million for the full year –]]>https://www.globenewswire.com/news-release/2021/01/11/2156125/0/en/GW-Pharmaceuticals-Provides-Preliminary-Fourth-Quarter-and-Full-Year-2020-Net-Product-Sales-Results-and-2021-Program-Milestones.html?f=22&fvtc=4&fvtv=20787GW Pharmaceuticals Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones2021-01-11T12:00:00Z<![CDATA[- Total preliminary net product sales of approximately $148 million for the fourth quarter and approximately $526 million for the full year -- Total Epidiolex® preliminary net product sales of approximately $144 million for the fourth quarter and approximately $510 million for the full year –- Pivotal US clinical program for nabiximols in MS spasticity underway. Initial data expected in 2021 -]]>https://www.globenewswire.com/news-release/2021/01/05/2153751/0/en/CORRECTING-and-REPLACING-GW-Pharmaceuticals-to-Present-at-the-39th-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=20787CORRECTING and REPLACING - GW Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference2021-01-05T17:24:39Z<![CDATA[LONDON and CARLSBAD, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- In a release issued earlier today by GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group) under the same headline, please note the time of the conference and breakout session have changed. The conference will be held Tuesday, January 12, 2021 at 10:00 am ET (7:00 am PT). The breakout session will follow at 10:20 am ET (7:20 am PT). Complete corrected release follows:]]>https://www.globenewswire.com/news-release/2021/01/05/2153357/0/en/GW-Pharmaceuticals-to-Present-at-the-39th-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=20787GW Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference2021-01-05T12:30:00Z<![CDATA[LONDON and CARLSBAD, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will present a business update and 2021 outlook at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:00 am PT (1:00 pm ET). In addition, a Q&A breakout session will immediately follow the presentation at 10:20 am PT (1:20 pm ET).]]>https://www.globenewswire.com/news-release/2020/12/21/2148882/0/en/JAMA-Neurology-Publishes-Phase-3-Study-of-EPIDIOLEX-cannabidiol-Oral-Solution-in-Patients-with-Seizures-Associated-with-Tuberous-Sclerosis-Complex.html?f=22&fvtc=4&fvtv=20787JAMA Neurology Publishes Phase 3 Study of EPIDIOLEX® (cannabidiol) Oral Solution in Patients with Seizures Associated with Tuberous Sclerosis Complex2020-12-21T16:30:00Z<![CDATA[EPIDIOLEX significantly reduced difficult-to-treat seizures, both focal and generalized EPIDIOLEX significantly reduced difficult-to-treat seizures, both focal and generalized]]>